Overall Well-Being Discussions may include sleep quality, daily energy, exercise recovery, physical activity, and other changes reported by the patient during follow-up visits
Over the last few years, several regulatory authorities, such as the FDA and EMA, reported the incidence of mood alterations, depressive symptoms, and even suicidal thoughts with the use of GLP-1 receptor agonists during the pharmacovigilance surveillance process, which raises the issue of their psychiatric safety [13,14,15]
In contrast, semaglutide, despite its growing clinical prominence as a weight loss therapy, exhibits minimal engagement with core neurodegenerative pathways within the DM2-AD comorbidity network
You can call us, stop by, or begin online